Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Divorcing diagnosis from treatment: contemporary management of low-risk prostate cancer.

Glass AS, Punnen S, Cooperberg MR.

Korean J Urol. 2013 Jul;54(7):417-25. doi: 10.4111/kju.2013.54.7.417. Epub 2013 Jul 15.

2.

An evidence review of active surveillance in men with localized prostate cancer.

Ip S, Dahabreh IJ, Chung M, Yu WW, Balk EM, Iovin RC, Mathew P, Luongo T, Dvorak T, Lau J.

Evid Rep Technol Assess (Full Rep). 2011 Dec;(204):1-341. Review.

3.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
4.

Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.

Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schröder FH, Roobol MJ.

BJU Int. 2012 Dec;110(11):1672-7. doi: 10.1111/j.1464-410X.2012.11434.x. Epub 2012 Aug 29.

5.

Insignificant prostate cancer and active surveillance: from definition to clinical implications.

Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schröder F.

Eur Urol. 2009 Jun;55(6):1321-30. doi: 10.1016/j.eururo.2009.02.028. Epub 2009 Mar 6. Review.

PMID:
19286302
6.

Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression.

Dall'Era MA, Konety BR.

Nat Clin Pract Urol. 2008 May;5(5):277-83. doi: 10.1038/ncpuro1058. Epub 2008 Feb 19. Review.

PMID:
18285752
8.

Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.

Mitsuzuka K, Narita S, Koie T, Kaiho Y, Tsuchiya N, Yoneyama T, Kakoi N, Kawamura S, Tochigi T, Habuchi T, Ohyama C, Arai Y.

BJU Int. 2013 May;111(6):914-20. doi: 10.1111/j.1464-410X.2012.11658.x. Epub 2013 Jan 15.

9.

Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.

Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S.

BJU Int. 2012 Feb;109 Suppl 1:22-9. doi: 10.1111/j.1464-410X.2011.10827.x. Review.

10.

Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.

Krakowsky Y, Loblaw A, Klotz L.

J Urol. 2010 Jul;184(1):131-5. doi: 10.1016/j.juro.2010.03.041. Epub 2010 May 15.

PMID:
20478589
11.

Active surveillance for low-risk prostate cancer: an update.

Lawrentschuk N, Klotz L.

Nat Rev Urol. 2011 Apr 26;8(6):312-20. doi: 10.1038/nrurol.2011.50. Review.

PMID:
21519351
12.

Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer.

Wilt TJ.

Semin Urol Oncol. 2002 Feb;20(1):10-7. Review.

PMID:
11828353
13.

Active surveillance for favorable-risk prostate cancer: a short review.

Lawrentschuk N, Klotz L.

Korean J Urol. 2010 Oct;51(10):665-70. doi: 10.4111/kju.2010.51.10.665. Epub 2010 Oct 21.

14.

Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.

Baade PD, Youlden DR, Gardiner RA, Ferguson M, Aitken JF, Yaxley J, Chambers SK.

BJU Int. 2012 Dec;110(11 Pt B):E712-9. doi: 10.1111/j.1464-410X.2012.011533.x. Epub 2012 Sep 27.

15.

[Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].

Leibovici D, Lindner A, Stay K, Zisman A.

Harefuah. 2006 Oct;145(10):763-7, 781, 780. Review. Hebrew.

PMID:
17111715
16.

Prostate cancer: the new landscape.

Moul JW, Mouraviev V, Sun L, Schroeck FR, Polascik TJ.

Curr Opin Urol. 2009 Mar;19(2):154-60. Review.

PMID:
19195129
17.

Conventional treatments of localized prostate cancer.

Zerbib M, Zelefsky MJ, Higano CS, Carroll PR.

Urology. 2008 Dec;72(6 Suppl):S25-35. doi: 10.1016/j.urology.2008.10.005.

PMID:
19095125
18.

Prostate specific antigen only progression of prostate cancer.

Moul JW.

J Urol. 2000 Jun;163(6):1632-42. Review.

PMID:
10799151
19.

Active surveillance for prostate cancer: overview and update.

Klotz L.

Curr Treat Options Oncol. 2013 Mar;14(1):97-108. doi: 10.1007/s11864-012-0221-5. Review.

PMID:
23318986
20.

Evaluating localized prostate cancer and identifying candidates for focal therapy.

Sartor AO, Hricak H, Wheeler TM, Coleman J, Penson DF, Carroll PR, Rubin MA, Scardino PT.

Urology. 2008 Dec;72(6 Suppl):S12-24. doi: 10.1016/j.urology.2008.10.004.

PMID:
19095124
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk